03:53 AM EDT, 07/09/2024 (MT Newswires) -- Emergent Biosolutions ( EBS ) said in a regulatory filing Monday that its subsidiary, Emergent Manufacturing Operations Baltimore, and Johnson & Johnson's ( JNJ ) Janssen Pharmaceuticals unit have agreed to settle all disputes related to a manufacturing services agreement for Johnson & Johnson's ( JNJ ) COVID-19 vaccine.

Under the settlement agreement, Janssen will pay Emergent $50 million, resolving all claims and arbitration between the parties.

Emergent rose more than 2% in after-market trading hours, while Johnson & Johnson ( JNJ ) was flat.

Price: 8.30, Change: +0.17, Percent Change: +2.09